DRL
Location
Vlaams Brabant
Founded
1980-09-05
Website
Risk Signals
105 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Furniture, Catalog and Mail-Order Houses), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about DRL
Live alerts from global media, monitored by Business Radar
2024-05-27 (pharmaceutical-technology.com)
Dr. Reddy's and Novartis sign agreement for anti-diabetes products
Dr. Reddy's Laboratories' Russian subsidiary and Novartis Pharma signed a deal for the distribution of anti-diabetes products.
Read more
(economictimes.com)
reddy: DRL acquires injectable portfolio from US-based Eton Pharma for $50 million -
The portfolio includes the Biorphen (phenylephrine hydrocholoride) injection and Rezipres (ephedrine hydrochloride) injection NDAs (new drug application) with nine separate combinations of strengths and presentations and one first- to-file approved ANDA for Cysteine Hydrochloride for the US.
Read more